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Gelsolin expression is frequently downregulated in lung cancer and several types of different human cancers. To examine the effects
of gelsolin restoration on tumorigenicity, we here stably expressed various levels of gelsolin via gene transfer in lung cancer cells
(squamous cell carcinoma line, PC10). We observed the alterations in tumorigenicity in vivo when implanted in nude mice, and the
changes in growth properties in vitro. As compared to parental cells and control clones, gelsolin transfectants highly reduced
tumorigenicity and repressed cell proliferation. Moreover, we investigated bradykinin-induced responses in gelsolin-overexpressing
clones, because agonist-stimulated activation of the phospholipases C (PLC)/protein kinase C (PKC) signal transduction pathway is
critical for cell growth and tumorigenicity. Bradykinin promotes phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis by PLC and
translocation of various PKC isoforms from the cytosolic fraction to the particulate fraction. Bradykinin treatment did not increase
inositoltriphosphate (IP3) production and induce the membrane fractions of PKCa and PKCg in gelsolin tranfectants, while it induced
PIP2 hydrolysis and increased the fractions in parental and control clones. These results suggest that gelsolin suppressed the activation
of PKCs involved in phospholipid signalling pathways, inhibiting cell proliferation and tumorigenicity.
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The long-term accumulation of genetic aberrations plays a major
role in the development of various cancers. Molecular abnormal-
ities include expression of oncogenes, such as Ki-ras, c-myc,c - erb-
B-2 and bcl-2, and tumour suppressor genes, such as p53, Rb and
FHIT (fragile histidine triad) in lung cancer (Otterson et al, 1998;
Salgia and Skarin, 1998).
We previously demonstrated that expression of an actin-
regulatory protein (Yin and Stossel, 1979), gelsolin, is frequently
downregulated in lung cancer (Dosaka-Akita et al, 1998) and
several types of different human cancers, such as stomach, bladder
and colon (Moriya et al, 1994; Tanaka et al, 1995; Furuuchi et al,
1996). Moreover, we indicated that introducing human cytoplas-
mic gelsolin cDNA suppresses tumorigenicity in human bladder
and colon cancer cell lines (Tanaka et al, 1995; Furuuchi et al,
1996). Gelsolin controls the length of actin polymers in vitro by a
variety of mechanisms. At least three different activities are
known: severing, capping and nucleating through interaction with
both filamentous (F-) and monomeric (G-) actins are responsible
for reorganisation of the actin cytoskeleton. These functions are
tightly regulated by calcium ions (Ca
2+), pH and polyphospho-
inositides (Janmey, 1994). Although gelsolin may modulate
phospholipid signaling pathways through its high affinity to
polyphosphoinositides (Janmey and Stossel, 1987), the mechanism
that restored gelsolin expression suppresses tumorigenicity in
cancer cells is not well understood.
Protein kinase C (PKC) belongs to a ubiquitous family of serine/
threonine kinases that plays a critical role in many signal
transduction pathways (Nishizuka, 1984). PKCs are activated by
a variety of extracellular stimuli that elicit production of a lipid
second messenger diacylglycerol (DAG) and a cofactor phospha-
tidylserine (PS) (Kishimoto et al, 1980; Nishizuka, 1992; Toker,
1998). Up to 12 different PKC isoforms have been reported in
mammalian cells (Dekker and Parker, 1994; Mellor and Parker,
1998). The isoforms have been divided into three distinct
subfamilies: the conventional PKCs (cPKCa, bI, II and g), which
are activated by DAG, PS and Ca
2+; novel PKCs (nPKCd, e, Z, y and
m), which are dependent on DAG and PS, but not on Ca
2+; and
atypical PKCs (aPKCz, i/l), which are activated by PS, but not by
DAG and Ca
2+ (Toker et al, 1994). Several studies have indicated
that the individual PKC isoforms express in their tissue specifically
and vary in biochemical properties and intracellular localisation
(Nishizuka, 1992).
PKCs are shown to be a target for phorbol ester, such as 12-O-
tetradecanoylphorbol-13-acetete (TPA) which is known as a
tumour promoter, because TPA contains a diacylglycerol-like
structure (Castagna et al, 1982; Gopalakrishna and Barsky, 1988).
Several studies showed that overexpression of different PKC
isoforms induces high growth rates, cellular saturation densities
and enhanced tumorigenicity (Housey et al, 1988; Persons et al,
1988; Cacace et al, 1993; Mischak et al, 1993; Borner et al, 1995).
Furthermore, the transfection of antisense PKCa into lung cancer
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scells repressed cell proliferation and reduced tumorigenicity in
nude mice (Wang et al, 1999). However, there are a number of
conflicting reports that overexpression of PKC increases or
suppresses tumorigenicity in various cells (Janik et al, 1994;
Johnson et al, 1999). These observations suggest that various PKCs
play various roles in carcinomas and distinctive roles in cell
regulation.
In this study, we established lung cancer cells (squamous cell
carcinoma, PC10) overexpressing human cytoplasmic gelsolin in
various degrees by gene transfer, using retrovirus carrying human
cytoplasmic gelsolin cDNA, and examined the effects of restoration
of gelsolin expression on tumorigenicity in vivo with nude mice
and growth properties in culture in vitro. Moreover, we
investigated bradykinin-induced responses, particularly inositol-
triphosphate (IP3) production and translocation of various PKC
isoforms from the cytosolic fraction to the particulate fraction in
gelsolin-overexpressing clones, because agonist-stimulated activa-
tion of the phospholipases C (PLC)/PKC signal transduction
pathway is critical for cell proliferation and tumorigenicity.
MATERIALS AND METHODS
Materials
Geneticin (G418) and LipofectAMINE were purchased from Life
Technologies. Bradykinin and anti-human gelsolin monoclonal
antibody (clone: GS-2C4) were from Sigma. An anti-actin
monoclonal antibody was from Boehringer Mannheim Biochem-
ica. Monoclonal antibodies to PKC isoforms were from Transduc-
tion Laboratories. Chemiluminescence kit (ECL system) was from
Amersham Pharmacia Biotech.
Cell culture
Human lung cancer cell PC10 (squamous cell carcinoma) obtained
from the Health Science Research Resources Bank of Japan (Osaka,
Japan) were grown in RPMI 1640, supplemented with 10% foetal
calf serum (FCS; Life Technologies) and 0.03% L-glutamine.
Culture was maintained at 371C in a moist atmosphere of 95%
air and 5% CO2.
Retrovirus construction for human cytoplasmic gelsolin
and gene transfer
Retroviral vector for the expression of human cytoplasmic gelsolin
(pLNChGsn) was constructed as described previously with pLNCX
(a generous gift from Dr AD Miller, Fred Hutchinson Cancer
Research Center) (Banno et al, 1999). Amphotropic retrovirus
containing gelsolin cDNA and empty virus were obtained by
transfection of each vector into CAK8 (kindly provided by Dr Karl
Riabowol, University of Calgary), a highly efficient virus-packa-
ging cell line, using LipofectAMINE. At 2 days after transfection,
virus-containing supernatants were recovered, spun with
1200r.p.m. and then used for infection with PC10 cells. Infected
cells were cultured in a selection medium containing 400mgml
 1
G418 for 14–20 days and individual colonies were picked
randomly and then expanded.
Western blotting and densitometric quantification
Total cell lysates were prepared by extracting the cell pellets with
RIPA buffer (50mM HEPES, 50mM NaCl, 0.1% SDS, 1% NP-40,
2m M EDTA, 2mM EGTA, 1mM phenylmethylsulphonyl fluoride
(PMSF), 5mgml
 1 leupeptin and 10mgml
 1 aprotinin). The
protein concentration was determined by the Bio-Rad protein
assay kit (Bio-Rad, Richmond, CA, USA) with bovine serum
albumin (BSA) as a standard. A portion equivalent to 20mgo f
protein was separated by SDS–PAGE and electrotransferred to
nitrocellulose membrane. After blocking with 5% nonfat dry milk
in TBST (Tris-buffered saline: 10mM Tris-HCl, pH 8.0 and 150mM
NaCl containing 0.05% Tween-20), they were probed with anti-
human gelsolin antibody (GS-2C4), 2nd antibody and then
visualised with the ECL system. Band images were scanned with
a GT-6000 Scanner (Epson-SEIKO) and densitometric analyses
were performed using NIH Image, ver. 1.56. Proteins were
normalised against the levels of actin protein.
Growth assay in monolayer culture and MTT assay
Cells were seeded at a density of 5 10
4 cells per well in six-well
plates in RPMI 1640 with either 10 or 1% FCS, respectively. This
point was designated day 0. Cells number in triplicate wells was
determined by counting with a haemocytometer after trypsinisa-
tion every 48h. Flat 96-well culture plates seeded at a density of
5 10
3cells per well were used to test growth with 1% FCS
medium by MTT assay. MTT was dissolved at 5mgml
 1 in
phosphate-buffered saline solution and used. After 40h, 10mlo f
MTT solution was directly added to the medium and the cells were
incubated for an additional 6h. After removal of the medium,
100ml of 0.04 N hydrochloric acid in isopropanol was added to each
well and the optical density of the plates was measured on a
microculture plate reader (Spectra Max 250; Molecular Devices)
using a test wavelength of 570nm and a reference wavelength of
630nm.
Cell death assay
Cells were treated with staurosporine (STS; Sigma), a potential
inducer of apoptotic cell death, at 250ngml
 1 and incubated for
various intervals. Cell death was examined with fluorescence
microscopy (TE-300; Nikon) for nuclear morphological changes
such as a nuclear condensation after an addition of Hoechst 33342
at a final concentration of 1mgml
 1. Apoptotic index was
determined by counting the number of apoptotic cells with a
nuclear condensation divided by the total number of cells (at least
300 cells) in the fields.
Anchorage-independent growth assay
For the assay of colony-forming efficiency in soft agar, 5 10
3 cells
in 1ml growth medium containing 0.33% Noble agar (DIFCO
Laboratories, Detroit, MI, USA) were incubated in a 60mm dish
with glids (Coster Scientific Co. Corning, NY, USA) overlaid on
4ml of 0.5% agar medium. Cells were incubated at 371C in a moist
atmosphere of 95% air and 5% CO2 and 3 weeks later the number
of colonies was counted using an inverted phase microscope. The
data are expressed as colony-forming efficiency ¼[(number of
colonies  100)/(number of cells originally seeded)].
Tumorigenicity in nude mice
Cells were trypsinised from monolayer cultures, counted, and spun
down with 1500r.p.m. for 5min and resuspended with RPMI 1640.
Two BALB/c-nu/nu syngenic 6-week-old male mice (Japan SLC,
Inc. Shiruoka, Japan) per clone were injected subcutaneously into
the back with 3 10
6 cells of gelsolin transfectants, neo-control or
parental PC10 cells in a final volume of 100ml of PBS. Tumour size
was measured using a hand calipers every 10 days. Volumes were
calculated by the formula 1/2 L W
2 where L and W are length
and width, respectively, of the tumour measured in two dimen-
sions. The animal experiments were conducted under the guide-
lines for the use of experimental animals laid down by the
Hokkaido University School of Medicine and the United Kingdom
Co-ordinating Committee on Cancer Research (UKCCCR) guide-
lines for the welfare of animals in experimental neoplasia
(Workman et al, 1998).
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sAssay for phospholipase C (PLC) activity
PLC activity was assessed by the measurement of total inositol
phosphates. Cells in six-well plates were prelabelled with
1mCiml
 1 myo-[
3H] inositol for 24h in inositol-free RPMI 1640
medium containing 0.3% BSA. Cells were then washed twice with
the HEPES/Tyrode buffer (10mM HEPES/NaOH, pH 7.4, 134mM
NaCl, 12mM NaHCO3, 2.9mM KCl, 0.36mM NaH2PO4, 1.0 mM
MgCl2, 1.8 mM CaCl2 1mgml
 1 BSA and 1mgml
 1 glucose)
containing 20mM LiCl and further incubated for 15min at 371C
before stimulation with agonists. Cells were then stimulated with
bradykinin at the indicated concentration for 2min, and the
reactions were terminated by the addition of ice-cold 10%
perchloric acid. Inositol phosphates were separated using AG
1 8 anion exchange resin (formate form, 200–400 mesh, Bio-
Rad) as described previously (Berridge et al, 1983).
Protein kinase C (PKC) translocation assay
Gelsolin transfectants, neo-control and parental PC10 cells were
cultured to 70–80% confluence on 150mm plates in complete
medium (RPMI 1640, supplemented with 10% FCS and 0.03% L-
glutamine). The cells were starved by serum-free RPMI 1640
medium for 48h before stimulation. After starvation, the cells were
exposed to bradykinin (100nM) for 5min at 371C in a moist
atmosphere of 95% air and 5% CO2. The cells were washed with
ice-cold phosphate-buffered saline, harvested with scraper, and
cell pellets were lysed with homogenisation buffer (20mM Tris-
HCl, pH 7.4, 250mM sucrose, 2mM EDTA, 10mM 2-mercaptoetha-
nol, 1mM PMSF, 5mgml
 1 leupeptin and 10mgml
 1 aprotinin) by
Dounce homogenisation (50 strokes). The homogenate was
centrifuged at 200 g for 10min to removed nuclei and unlysed
cell, and the resulting supernatant was centrifuged at 100000 g
for 1h. The supernatants (soluble fraction) were analysed for
protein content and prepared for electrophoresis (Rotenburg and
Sun, 1998). The pellets (particulate fraction) were resuspended
with RIPA buffer containing 0.1% Triton X-100, placed at 41C
overnight. Soluble (cytosol) and particulate (membrane) fractions
(20mg per lane) were separated with 10% of polyacrylamide gel
and analysed by Western blot analysis with monoclonal antibodies
specific for PKC isoforms.
RESULTS
Establishment of lung cancer cell line overexpressing
gelsolin
The protein level of gelsolin in PC10 cells was 1/30th in
comparison with that of normal lung tissues on Western blot
analysis (Dosaka-Akita et al, 1998). To stably transduce gelsolin
into lung cancer cells, we obtained amphotropic retrovirus
carrying the human cytoplasmic gelsolin cDNA (designated as
RGV) through transient transfection of CAK8 packaging cells with
pLNChGsn (Figure 1A). An empty vector pLNCX containing only
neomycin-resistance gene was generated as control virus (desig-
nated as RNV). The lung squamous cell carcinoma PC10 was
infected with either RGV or RNV and selected with G418. Initially,
six clones infected with RGV were designated as PG and four
clones infected with RNV were designated as PN. They were
randomly selected and gelsolin expression was confirmed against
the parental cell clones on Western blot analysis. Gelsolin
expressions in PG clones were higher than those of control cells,
PN and PC10 (data not shown). PG2, PG3, PN3 and PN4 clones as
well as PC10 were used for this experiment. Gelsolin expressions
were verified on Western blot and quantified on densitometric
analysis (Figure 1B, C). Gelsolin protein levels were about 5.0- and
7.5-fold higher in PG3 and PG2 cells, respectively, than the
parental clone.
Tumorigenicity of gelsolin-overexpressing clones in vitro
and in vivo
We next examined the effects of restoration of gelsolin expression
on tumorigenicity of PC10 in soft agar and in nude mice. As shown
in Figure 2, colony formation was significantly reduced by
overexpression of gelsolin in PC10 (Po0.05). Next, we tested the
tumorigenecity of gelsolin-overexpressing clone PG2 and the neo-
control clone PN3 in nude mice. The tumorigenicity of PG2 was
suppressed as compared to PN3 in Exp. 1 (Table 1). In Exp. 2, the
implanted PG2 and PG3 cells overexpressing gelsolin grew more
slowly than PN3 control cells and PC10 parental cells in nude mice,
indicating that tumorigenicity of PG2 and PG3 clones was strongly
suppressed, in parallel with the amounts of expressed gelsolin
(Figure 3). Furthermore, PG2 cells regressed in both mice tested in
Exp. 2 (Table 1). These results demonstrated that gelsolin
functioned as a tumour suppressor in lung cancer cells, consistent
with previous observations in bladder and colon cancers (Tanaka
et al, 1995; Furuuchi et al, 1996).
Cell growth and apoptosis in vitro
It has been proposed that the balance between cell proliferation
and apoptosis determines tumour growth in vivo (Reed, 1999). We
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Figure 1 Identification of human lung cancer cells transfected with
gelsolin. (A) Construction of gelsolin-overexpressive clones. The human
cytoplasmic gelsolin cDNA was cloned into the HindIII–StuI site of pLNCX
retoroviral vector as described in Materials and Methods. The resulting
construct, pLNChGsn or pLNCX alone was transfected into CAK8, a highly
efficient ecotropic virus-packaging cell line. (B) Western blot analysis of the
gelsolin expression in stably transfected clones. PC10 cells were transfected
with pLNCX or pLNChGsn, and stable transfectants were established after
selection with G418 as described in Materials and Methods. Parental (lanes
1), neo-transfectants (lanes 2 and 3) and gelsolin transfectants (lanes 4 and
5) are shown. (C) Densitometric quantification of protein levels in
transfectants is shown after normalisation against the levels of actin protein
using NIH Image.
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snext studied in vitro whether gelsolin overexpression led to
tumour regression because cell proliferation was restrained or
because the apoptotic process was enhanced in PGs or both. The
cell growths of the transfectants, control cells and parental cells
were examined in a medium containing 10 or 1% FCS. The two
clones PG2 and PG3 transfected with gelsolin cDNA grew more
slowly than the control cells under 1% FCS condition (Figure 4A).
Under 10% FCS condition, there was no difference in the growth
rates (data not shown). Similarly, MTT assay indicated that
gelsolin transfection subdued cell growth (Figure 4B). In contrast,
apoptotic rates assayed by counting cells sensitive to staurosporine
were similar among the PGs, PNs and PC10 (data not shown). It
was suggested that gelsolin suppressed tumour growth in vivo by
affecting the cell-proliferating ability of PC10 rather than by
inducing apoptosis.
Inositol triphosphate (IP3) production in response to
bradykinin treatment
Gelsolin exhibits an ability of binding to phosphatidylinositol 4,5-
bisphosphate (PIP2), and inhibits PLC activity by competing with
PIP2 (Banno et al, 1992; Sun et al, 1997). Moreover, gelsolin
overexpression has recently been reported to suppress bradykinin-
induced PLC and phospholipase D (PLD) in NIH3T3 cells (Banno
et al, 1999). These results indicate that gelsolin functions as a
modulator of lipid metabolism in fibroblast cells. As shown in
Figure 5, IP3 production by treatment with bradykinin was
markedly inhibited in PG2, overexpressing gelsolin as compared to
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Figure 2 Effects of gelsolin expression on the colony-forming ability of
transfectants in soft agar. Parental PC10, neo-transfectants PN3, PN4 and
gelsolin transfectants PG3, PG2 cells were plated in 0.33% agar on 60mm
plates and the rate of colony forming at 3 weeks after incubation was
analysed. *Po0.05, compared with parental and neo-transfectant cells by
post hoc test.
Table 1 Tumorigenicity in nude mice of human lung cancer cell line
(PC10) or infected with gelsolin expression virus (LNChGsn) or neo-
control virus (LNCX)
Tumour incidence
Tumour volume at killing
(days: 60, mean) (mm
3)
Cell line Exp. 1 Exp. 2 Exp. 1 Exp. 2
PC10 2/2 710
PN3 2/2 2/2 1128 1678
PG3 2/2 22
PG2 1/2 0/2
a 242 0
The indicated cells were grown as described in Materials and Methods. Two mice per
clone were injected subcutaneously into the back with 3 10
6 cells in a final volume
of 100ml of BS. Tumour size was measured using a hand calipers every 10 days.
Volumes were calculated as described in Materials and Methods.
aTumours were regressed at days 24 or 50 later Inoculation.
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Figure 3 Effects of gelsolin expression on tumorigeneseity in nude mice.
Cells (3 10
6) were inoculated subcutaneously into the back of BALB/c-
nu/nu syngenic 6-week-old male mice. Tumour size was measured using a
hand calipers every 10 days as described in Materials and Methods.
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Figure 4 Growth properties of wild-type, neo- and gelsolin transfectant
cell lines. (A) Growth curve of parent, neo- and gelsolin transfectants. Cells
were seeded at a density of 5 10
4 cells per well in six-well plates in RPMI
1640 with either 10 or 1% FCS as described in Materials and Methods. Cell
number in triplicate wells was determined by counting with a haemocyt-
ometer after trypsinisation every 24h. (B) Cell growth was also examined
by MTT assay as described in Materials and Methods. Flat 96-well culture
plates seeded at a density of 5 10
3cells per well were used to test
growth with 1% FCS medium. The optical density of the plates was
measured on a microculture plate reader using a test wavelength of 570nm
and a reference wavelength of 630nm.
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sin the neo-control clone PN3, indicating that PLC activity was also
suppressed by overexpression of gelsolin in the epithelial cell
system.
Translocation of PKC isoforms induced by bradykinin
Among the different PKC isoforms, the conventional and the novel
PKCs have been demonstrated to be activated by diacylglycerol
(DAG) or phorbol esters or both (Toker, 1998). Activation of PKCs
is a crucial step in the intracellular signal transduction pathway
common to many growth factors (Hunter, 1997). Tumour cells
with an increased PKC activity have an enhanced ability to invade
and metastasise, indicating PKC roles critical to malignant
phenotypes (Korczak et al, 1989; Schwartz et al, 1990). Western
blotting of whole cell extracts showed that PC10 cells expressed the
PKC isoforms a, g, i and l (data not shown). Gelsolin inhibits the
hydrolysis of PIP2 by PLC as described above, and thereby
suppresses the generation of DAG. For studying the activation
mechanism, we examined the stimulus-induced translocation of
PKC isoforms from the cytosolic fraction to the particulate
fraction. After treatment with 12-O-tetradecanoylphorbol-13-acet-
ete (TPA) (1000ngml
 1) for 1h, the membrane fractions of
conventional PKCs, PKCa and PKCg increased in all cells,
indicating no defect of the PKC pathway in transfectants
overexpressing gelsolin as well as the neo-control clones and
parental PC10 cells. In addition, the translocation of the atypical
PKC isoforms (i and l) was not observed in all cells as expected
(data not shown). As carried out in the other studies of
bradykinin-induced translocation of PKC isoforms in different
cell lines (Graness et al, 1998), PC10 and transfected cells were
stimulated with 100nM bradykinin for 5min. The membrane
fractions of PKCa and PKCg increased in PC10 and PN3 cells when
treated with bradykinin. On the other hand, in PG2 and PG3 cells
treated with bradykinin, PKCa and PKCg did not change in
membrane fractions. Furthermore, the atypical PKC isoforms l did
not translocate in any clones when treated with bradykinin
(Figure 6). Our results suggested that gelsolin suppressed the
activation of PKC by decreasing the production of DAG.
Collectively, our results indicate that overexpression of gelsolin
in PC10 cells causes tumour suppression in nude mice through
inhibiting the activation of PKCs by sequestering PIP2, which is a
substrate of PLC.
DISCUSSION
In this study, we demonstrated that gelsolin suppressed tumor-
igenicity of PC10 lung cancer cells through inhibiting a PKC signal
transduction pathway. Gelsolin is a representative of actin-
regulatory proteins with an 82kDa mass and is present in most
vertebrate tissues (Kwiatkowski et al, 1988; Lueck et al, 1998). Its
actions are regulated positively by calcium ions or protons, and
negatively by polyphosphoinositides, especially by PIP2, suggested
by the ability of gelsolin to bind to PIP2 (Janmey and Stossel, 1987;
Janmey, 1994). We previously reported that gelsolin expression is
reduced or not detected in various lung cancer cell lines and in
more than half of the surgically resected tissues (Dosaka-Akita
et al, 1998), and demonstrated that ectopic expression of gelsolin
cDNA in bladder and colon cancer cell lines results in suppression
of tumorigenicity (Tanaka et al, 1995; Furuuchi et al, 1996).
Activation of proto-oncogenes or inactivation of tumour
suppressor genes by either mutation, amplification or rearrange-
ment of DNA has been shown to be a critical step for
carcinogenesis (Hunter, 1997). Tumour suppressor genes are
classified into two categories, class I and class II. In class I tumour
suppressor genes, usually isolated by positional cloning strategy,
including RB, p53 or APC, loss of their function results from
mutation or deletion of DNA. An increasing number of class II
tumour suppressor genes have been identified on the basis of their
downregulated expressions and of their transformation-inhibitory
activity in tumour cells (Sager, 1997; Zhang et al, 1998). All these
findings suggest that downregulation of gelsolin is involved in the
development of various cancers as one of the early events in
carcinogenesis, and that gelsolin may function as a tumour
suppressor.
We established stable clones of lung cancer cells overexpressing
various levels of gelsolin to investigate the effects of gelsolin
restoration on tumorigenicity. In our studies, gelsolin-overexpres-
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Figure 5 Effects of gelsolin overexpression on PLC activation induced by
bradykinin. Vector (PN3)- or gelsolin (PG2)-overexpressing PG10 cells
were labelled wtih [
3H]inositol in inositol-free RPMI 1640 containing 0.3%
BSA for 24h. [
3H]inositol phosphate generation was measured at indicated
concentrations of bradykinin for 2min as described in Materials and
Methods. Results represent the mean7s.e. of three independent
experiments.
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Figure 6 Bradykinin-induced PKCs translocation in transfectants by
Western blot analysis. For activation studies, the bradykinin-induced
translocation of PKC isoforms from the cytosolic fraction to the membrane
fraction was investigated by cell fractionation as described in Materials and
Methods. Cytosol and membrane fractions (20mg per lane) were separated
with 10% polyacrylamide gel and analysed by Western blot analysis with
monoclonal antibodies specific for PKC isoforms. The PKC proteins are
represented by the arrows. C, cytosolic fractions; M, membrane fractions.
Inhibition of PKC activation by gelsolin
N Sagawa et al
610
British Journal of Cancer (2003) 88(4), 606–612 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
ssing lung cancer cells exhibited a significant growth inhibition
under the low-level serum condition, consistent with our previous
findings (Ishizaki et al, 1995), decreased the ability of colony
formation in soft agar and reduced tumorigenicity in nude mice.
PG2, highly expressing gelsolin, reduced and finally lost
tumorigenicity, whereas PG3, moderately expressing gelsolin,
slightly grew in nude mice. These findings demonstrated that
gelsolin played a key role as a tumour suppressor in lung cancer
cells and that the effect depended on the levels of gelsolin
expression.
Agonist-stimulated activation of PLC b, g and d subtypes
resulted in hydrolysis of membrane inositol phospholipid PIP2
(Williams, 1999), and led to the generation of DAG and soluble
IP3. It is likely that gelsolin may affect the phospholipid signalling
pathway after the hydrolysis of PIP2 supported by its high affinity
for PIP2. PLC activity is also reported to be modulated in NIH3T3
cells overexpressing wild-type gelsolin or CapG, an actin-capping
protein structurally related with gelsolin (Sun et al, 1995; Sun et al,
1997). Our group found that phospholipase D activity is affected by
overexpression of human gelsolin cDNA in NIH3T3 cells via PLC/
PKC pathway (Banno et al, 1999).
PKC isoforms appear to be localised in the cytoplasm before
stimulation. For example, in MCF-7 cells, PKCa is present in the
cytosol before stimulation, and 12-O-tetradecanoylphorbol-13-
acetete (TPA) treatment induces translocation of PKCa from the
soluble fraction to the particulate fraction (Kennedy et al, 1992).
To demonstrate activation of PKCs in our experiments, their
stimulus-induced translocation from the cytosol to the membrane
was investigated. We identified two types of PKC isoforms in PC10
cells: conventional PKC (PKCa and PKCg) and atypical PKC (PKCi
and PKCl). By TPA treatment, translocation of cPKCs was
observed in parental cells, control and gelsolin transfectants.
However, aPKC translocation was not detected in any cells by the
same stimulation.
Bradykinin binds to a seven transmembrane domain receptor
coupled with G-protein (Burch and Axelrod, 1987), activating
PLCb. PLCb hydrolyses PIP2, resulting in the generation of DAG,
which in turn activates PKC. As shown in Figure 4, translocation of
PKCa and g, but not that of PKCi/l, was observed in PC10 and PN3
in response to bradykinin treatment, whereas the translocation was
hampered in PG2, suggesting that activation of PKCa and g was
inhibited in PG2. We also examined the translocation of PKCs in
parental cells, control and gelsolin transfectants by epidermal
growth factor (EGF) treatment. PIP2 is hydrolysed to DAG and IP3
by PLCg, which EGF phosphorylates on its tyrosine residues
(Goldschmidt-Clermont et al, 1991). However, we did not detect
EGF-induced translocation of PKCs in either clone (data not
shown). These results indicated that overexpression of gelsolin
inhibited the PLCb/PKC pathway critical for the growth of PC10
cells, leading to the loss of tumorigenicity. Gelsolin could have a
regulatory function in the lipid signalling pathway not only in the
fibroblast system but also in epithelial cells. Tumour promotion in
PC10 cells mostly depended on the PKC signal transduction
pathway mediated by the activation of PLCb. Consistent with our
findings, stable transfection of PKCa antisense was documented to
decrease the malignant phenotypes of the parental cells (Wang
et al, 1999). This observation supported our findings that gelsolin
inhibited the activation of PKC in lung cancer cells and reduced
their growth and tumorigenicity (Figure 7).
In conclusion, we showed that, in PC10 cells, gelsolin suppressed
the activation of PKCs involved in phospholipid signalling
pathways and inhibited cell growth and tumorigenicity in nude
mice. Further biological researches on gelsolin will certainly be
required in order to exploit the tumour-suppressing effect of
gelsolin expression in the clinical field. For the present, the p53
gene transfer using an adenovirus vector has been used as a
tumour suppressor for gene therapy in nonsmall-cell lung
cancers (Roth et al, 1999). The introduction of gelsolin into
various cancers might possibly serve as an antitumour gene
therapy in the future.
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